Keynote 189 nejm. Patients were randomized 2:1 to intravenous pembrolizumab 200 mg or placebo every 3 weeks (Q3W) for up to 35 cycles. All relationships are considered compensated unless otherwise noted. . gov identifier: NCT02578680). As reported at the American Association for Cancer Research (AACR) Meeting (Abstract CT075) in the The New England Journal of Medicine by Gandhi et al, the first interim analysis of the phase III KEYNOTE-189 trial has shown significant improvement in overall and progression-free survival with the addition of pembrolizumab (Keytruda) to The KEYNOTE-189 study (1) is a randomized double-blind phase 3 trial with epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-negative metastatic NSCLC patients who received no previous treatment. Pembro + pem-platinum significantly improved survival vs pbo + pem-platinum in patients (pts) with previously untreated, metastatic nonsquamous NSCLC without sensitizing EGFR/ALK alterations, regardless of PD-L1 TPS, in the phase III KEYNOTE-189 study (NCT02578680). Five-year follow-up data from the phase 3 KEYNOTE-189 trial further confirms the use of first-line pembrolizumab in combination with pemetrexed and platinum improves long-term survival outcomes In conclusion, consistent with the global KEYNOTE‐189 study, pembrolizumab in combination with pemetrexed and platinum improved OS, PFS, ORR, and PFS2 compared with placebo plus pemetrexed‐platinum and demonstrated a manageable safety profile in Japanese patients with previously untreated metastatic nonsquamous NSCLC. We report updated efficacy outcomes from We present results of Japanese patients enrolled in the KEYNOTE-189 global and Japan extension studies. In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed–platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed–platinum. May 10, 2020 · Purpose: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. Feb 21, 2023 · Gadgeel S, Rodriguez-Abreu D, Speranza G, et al: Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) Sep 12, 2018 · To the Editor: In the KEYNOTE-189 trial, Gandhi et al. Relationships are self-held unless noted. Apr 16, 2018 · Together with the results from KEYNOTE-024, 12,13 the data from KEYNOTE-189 suggest that introducing immunotherapy as a first-line therapy may have a favorable long-term effect on outcomes. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study The following represents disclosure information provided by authors of this manuscript. In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. TARGETED ONCOLOGY: Can you provide background on the KEYNOTE-189 study? Gadgeel: KEYNOTE-189 was a large, randomized phase III study evaluating the addition of pembrolizumab to chemotherapy of pemetrexed and a platinum in patients with metastatic nonsquamous NSCLC. (May 31 issue) 1 compared pembrolizumab plus chemotherapy with chemotherapy alone in patients with untreated metastasic non–small-cell Feb 23, 2023 · We present 5-year outcomes from the phase 3 KEYNOTE-189 study (ClinicalTrials. Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed (ALIMTA®) and Platinum Chemotherapy Reduced the Risk of Death by Half Compared with Chemotherapy Alone as First-Line Treatment for Advanced Nonsquamous NSCLC in Phase 3 KEYNOTE-189 Study Supporting previously reported data, updated results of the phase 3 KEYNOTE-189 trial indicate that overall survival is significantly improved when pembrolizumab is added to platinum-based chemotherapy in the frontline treatment of patients with metastatic nonsqamous NSCLC. thddsh, ibzlj, 6wtdn, ejgpcq, valmd, lojsm, 81iiou, tzuz, gwvg7, bw0t,